Literature DB >> 19056798

Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.

L G Hanitsch1, G-R Burmester, C Witt, N Hunzelmann, E Genth, T Krieg, W Lehmacher, I Melchers, M Meurer, U Müller-Ladner, E Schulze-Lohoff, M Becker, C Sunderkoetter, G Riemekasten.   

Abstract

OBJECTIVES: In SSc, diagnosis and classification is based mainly on skin sclerosis. Herein, we investigated in a large multicentre cohort, to what extent skin sclerosis reflects organ involvement and additional clinical symptoms.
METHODS: A total of 1200 SSc patients from the register of the German Systemic Sclerosis Network (DNSS), classified as either lcSSc or dcSSc, were analysed for their serological characteristics, clinical symptoms and organ manifestations in relation to skin involvement measured by the modified Rodnan skin score (mRSS).
RESULTS: SSc patients with different mRSS did not differ significantly in their disease duration and in most of the clinical symptoms. They showed a similar distribution of most organ manifestations such as pulmonary arterial hypertension as well as cardiac, renal and nervous system involvement. More severe skin thickening was found to be associated with pulmonary fibrosis and gastrointestinal symptoms, as well as with digital ulcers and musculoskeletal involvement.
CONCLUSIONS: In patients with SSc, potentially life-threatening complications and clinical symptoms with high impact on the quality of life occur independently from the extent of skin sclerosis. The diagnosis in SSc patients with a low mRSS could be missed or they could be insufficiently treated.

Entities:  

Mesh:

Year:  2009        PMID: 19056798     DOI: 10.1093/rheumatology/ken408

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

Review 1.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

2.  [Common German language nomenclature for systemic sclerosis].

Authors:  M Aringer; U Müller-Ladner; H Burkhardt; J H W Distler; O Distler; W B Graninger; C Günther; N Hunzelmann; H Kiener; M Sticherling; C Sunderkötter; U A Walker; G Riemekasten
Journal:  Z Rheumatol       Date:  2015-03       Impact factor: 1.372

Review 3.  Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling.

Authors:  Jennifer L Sargent; Michael L Whitfield
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

Review 4.  [The German network for systemic sclerosis (DNSS): current data on diagnostics and therapy].

Authors:  N Hunzelmann; T Krieg
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

5.  Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.

Authors:  Michael D Roth; Chi-Hong Tseng; Philip J Clements; Daniel E Furst; Donald P Tashkin; Jonathan G Goldin; Dinesh Khanna; Eric C Kleerup; Ning Li; David Elashoff; Robert M Elashoff
Journal:  Arthritis Rheum       Date:  2011-09

6.  Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms.

Authors:  Stefan Schanz; Jörg Henes; Anja Ulmer; Ina Kötter; Gerhard Fierlbeck; C D Claussen; Marius Horger
Journal:  Eur Radiol       Date:  2012-07-29       Impact factor: 5.315

7.  Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study.

Authors:  Karen Au; Maureen D Mayes; Paul Maranian; Philip J Clements; Dinesh Khanna; Virginia D Steen; Donald Tashkin; Michael D Roth; Robert Elashoff; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-12       Impact factor: 4.794

8.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.

Authors:  Tricia R Cottrell; Robert A Wise; Fredrick M Wigley; Francesco Boin
Journal:  Ann Rheum Dis       Date:  2013-04-20       Impact factor: 19.103

Review 9.  Rheumatic manifestations of skin disease.

Authors:  Jennie T Clarke; Victoria P Werth
Journal:  Curr Opin Rheumatol       Date:  2010-01       Impact factor: 5.006

10.  Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.

Authors:  Katharina Hanke; Cornelia Dähnrich; Claudia S Brückner; Dörte Huscher; Mike Becker; Anthonina Jansen; Wolfgang Meyer; Karl Egerer; Falk Hiepe; Gerd R Burmester; Wolfgang Schlumberger; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-02-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.